Abstract CT253: HERIZON-BTC-302: A phase 3 trial of zanidatamab with standard-of-care therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer | Publicación